- Condition: HIV Dementia
Interventions: Drug: Lipitor; Drug: placebo
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified May 2012 - Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate; Drug: Long acting methylphenidate; Drug: Matched placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified May 2012 - Condition: Melanoma
Interventions: Drug: Vemurafenib; Drug: IL-2; Drug: Interferon Alpha-2b
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012 - Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral; Drug: GSK1265744 LAP 800mg intramuscular injection; Drug: GSK1265744 LAP 200mg subcutaneous injection; Drug: GSK1265744 LAP 200mg intramuscular injection; Drug: GSK1265744 LAP 400mg intramuscular injection; Drug: TMC278 LA 1200mg intramuscular injection; Drug: TMC278 LA 600mg intramuscular injection; Drug: GSK1265744 LAP 800mg intramuscular injection
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Not yet recruiting - verified May 2012 - Conditions: HIV; Bone Mineral Density; Bone Turnover; Fracture
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified May 2012 - Condition: Tuberculosis
Intervention:
Sponsors: Cepheid; Cepheid; AIDS Clinical Trials Group; Centers for Disease Control and Prevention
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Efavirenz; Drug: Rilpivirine
Sponsors: Indiana University; Indiana University; Janssen Services, LLC
Not yet recruiting - verified April 2012 - Condition: Staphylococcus Aureus
Interventions: Drug: XF-73 in 2% gel; Other: Placebo in 4% gel; Drug: XF-73 in 4% gel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012 - Conditions: Sarcoma; Solid Tumors; Pulmonary Metastases; Lung Metastases; Osteosarcomas; Ewing Sarcoma
Interventions: Drug: Aerosol IL-2; Procedure: Symptom Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Shannon Wilkes Foundation
Not yet recruiting - verified May 2012 - Condition: Pulmonary Artery Hypertension
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine; Biological: IL-12 pDNA adjuvant; Biological: VSV HIV gag vaccine; Biological: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Cervical Cancer; Oropharyngeal Cancer; Vaginal Cancer; Anal Cancer; Penile Cancer
Interventions: Drug: Fluderabine; Drug: Cycolphosphamide; Biological: Young TIL; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Cancer; Melanoma
Interventions: Drug: Vemurafenib; Drug: Young TIL; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Metastatic Cancer; Pancreatic Cancer; Mesothelioma
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Biological: Aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Biological: GEO-D03 DNA vaccine; Biological: MVA/HIV62B (MVA62B) vaccine; Biological: Placebo for GEO-D03 DNA; Biological: Placebo for MVA62B:
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); GeoVax, Inc.
Not yet recruiting - verified May 2012 - Condition: Sexual Transmission of Infection
Interventions: Behavioral: HIV prevention intervention; Behavioral: Diet and Nutrition; Other: Standard of care
Sponsors: Children's Memorial Hospital; Children's Memorial Hospital; National Institute of Mental Health (NIMH)
Recruiting - verified April 2012 - Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily; Drug: dolutegravir placebo twice daily; Drug: Open-label dolutegravir 50mg twice daily
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: darunavir/cobicistat/emtricitabine/GS-7340; Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Epilepsy
Intervention:
Sponsors: Columbia University; Columbia University; Epilepsy Foundation; University of Nebraska
Recruiting - verified March 2012 - A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated MyelopathyCondition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; David M. Simpson; CSL Behring
Recruiting - verified March 2012 - Condition: Substance-Related Disorders
Intervention: Drug: naltrexone for extended release injectable suspension
Sponsors: Rhode Island Hospital; Rhode Island Hospital; National Institute on Drug Abuse (NIDA); Alkermes
Recruiting - verified March 2012 - Conditions: HIV; Patient Compliance
Interventions: Behavioral: Positive Choices; Behavioral: Personalized Cognitive Counseling
Sponsors: Columbia University; Columbia University; National Institute of Mental Health (NIMH)
Not yet recruiting - verified March 2012 - Condition: Tuberculosis
Interventions: Drug: PA-824; Drug: Efavirenz (EFV); Drug: Lopinavir/Ritonavir (LPV/r); Drug: Rifampin (RIF)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Conditions: Substance-related Disorders; HIV Risk Behavior
Interventions: Behavioral: Therapeutic Workplace; Drug: Methadone
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified March 2012 - Conditions: Inflammation; Macrophage Infiltration; Cardiovascular Disease
Interventions: Drug: Sitagliptin; Drug: Placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012 - Condition: HIV-Associated Cognitive Motor Complex
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified December 2011 - Condition: Sexually Transmitted Diseases
Interventions: Behavioral: Horizons+General Health Promotion (GHP); Behavioral: Horizons+Motivational Enhancement Therapy (GMET)
Sponsors: Emory University; Emory University
Recruiting - verified May 2012 - Condition: HIV
Interventions: Genetic: SB-728-T; Genetic: SB-728-T; Genetic: SB-728-T
Sponsors: Sangamo Biosciences; Sangamo Biosciences
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film; Drug: Dapivirine Vaginal Gel
Sponsors: International Partnership for Microbicides, Inc.; International Partnership for Microbicides, Inc.
Not yet recruiting - verified March 2012 - Condition: HIV-1 Infection
Intervention: Drug: Sevelamer carbonate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel; Drug: Universal HEC Placebo Gel Formulation
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel; Drug: Vaginal formulation (VF) of tenofovir 1% gel; Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel; Radiation: Radiolabeling of study drugs and semen
Sponsors: University of Pittsburgh; Ian McGowan; National Institute of Allergy and Infectious Diseases (NIAID); CONRAD
Not yet recruiting - verified April 2012 - Condition: Sexually Transmitted Diseases
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified April 2012 - Conditions: Pregnancy; Sexually Transmitted Infections
Interventions: Behavioral: BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved; Behavioral: DIVAS. Diversity, Individuality, Vitality, Activity and Strong.
Sponsors: Tulane University Health Sciences Center; Tulane University Health Sciences Center; Department of Health and Human Services
Not yet recruiting - verified April 2012 - Condition: Plasma Cell Myeloma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Procedure: Apheresis
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Positive
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: HIV Positive; Marijuana Smoking
Intervention:
Sponsors: Wayne State University; Wayne State University; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Hydroxychloroquine; Drug: IL-2
Sponsors: University of Pittsburgh; University of Pittsburgh; Prometheus Laboratories
Recruiting - verified March 2012 - Conditions: Diabetic Neuropathy; Chemotherapy Induced Neuropathy; HIV Neuropathy; Trauma Induced Neuropathy
Intervention: Drug: Neuron012703 (Medical Food)
Sponsors: Targeted Medical Pharma; Targeted Medical Pharma
Not yet recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Lisinopril; Drug: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; American Foundation for AIDS Research
Recruiting - verified February 2012 - Conditions: Adolescent HIV Prevention; Adolescent Unintended Pregnancy
Intervention: Behavioral: combination HIV prevention package for boys and girls
Sponsors: New York University; New York University; University of Nairobi
Not yet recruiting - verified April 2012 - Condition: HIV
Intervention: Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Sponsors: Fenway Community Health; Kenneth H. Mayer, MD; Bristol-Myers Squibb; Gilead Sciences; Abbott
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Condition: Endothelial Dysfunction
Intervention: Drug: Telmisartan
Sponsors: University of California, Los Angeles; University of California, Los Angeles; The Campbell Foundation
Not yet recruiting - verified April 2012 - Condition: Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: HIV+
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: University Hospitals of Cleveland; University Hospitals of Cleveland; Emory University
Recruiting - verified January 2012 - Condition: Atherosclerosis
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: Lymphoma
Interventions: Drug: Lamivudine; Drug: Tenofovir disoproxil fumarate
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline; Gilead Sciences
Not yet recruiting - verified February 2012 - Condition: AIDS/HIV PROBLEM
Intervention:
Sponsors: Gaia Medical Institute; Gaia Medical Institute; AIDS Healthcare Foundation
Recruiting - verified January 2012 - Conditions: Sexually Transmitted Infection; HIV
Interventions: Behavioral: Tailored Socio-Contextual Intervention; Behavioral: Standard of Care
Sponsors: University of Wisconsin, Milwaukee; University of Wisconsin, Milwaukee; National Institute of Mental Health (NIMH)
Not yet recruiting - verified January 2012 - Condition: HIV Infection
Interventions: Drug: Maraviroc; Drug: Emtricitabine; Drug: Tenofovir disoproxil fumarate; Other: Maraviroc placebo; Other: Emtricitabine placebo; Other: Tenofovir disoproxil fumarate placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Prevention Trials Network
Not yet recruiting - verified May 2012 - Condition: HIV
Intervention: Behavioral: Care management
Sponsors: University of Washington; University of Washington; National Institutes of Health (NIH); National Institute of Mental Health (NIMH); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting - verified January 2012 - Conditions: Substance Use; Sexual Risk Behaviors
Interventions: Behavioral: Risk Reduction Therapy for Adolescents; Behavioral: Usual services
Sponsors: Medical University of South Carolina; Medical University of South Carolina
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified March 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV/AIDS-associated Fatigue
Interventions: Dietary Supplement: American ginseng (Panax quinquefolius); Dietary Supplement: Placebo
Sponsors: Johns Hopkins University; Johns Hopkins University; National Center for Complementary and Alternative Medicine (NCCAM)
Not yet recruiting - verified December 2011 - Condition: Chronic Pain
Intervention: Behavioral: Therapeutic Education System (TES) for chronic pain
Sponsors: National Development and Research Institutes, Inc.; National Development and Research Institutes, Inc.; National Institute on Drug Abuse (NIDA); Beth Israel Medical Center
Not yet recruiting - verified December 2011 - Condition: Sexual Transmission of Infection
Interventions: Biological: Gardasil Vaccine; Biological: Placebo Vaccine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Not yet recruiting - verified May 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Mestatic Melanoma; Skin Cancer
Interventions: Drug: Fludarabine; Drug: Cycolphosphamide; Drug: Aldesleukin; Drug: MART-1 Reactive CD8+ PBL
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: HIV; Sexual Risk; Sexually Transmitted Diseases; Substance Abuse; Violence; Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC); Biological: Test, Treat, Retain(TTR) only
Sponsors: RTI International; RTI International; University of North Carolina, Chapel Hill
Not yet recruiting - verified December 2011 - Condition: Substance Abuse
Intervention: Other: STaRS
Sponsors: Polaris Health Directions; Polaris Health Directions; University of Massachusetts, Worcester
Not yet recruiting - verified December 2011 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN); Drug: Ribavirin (RBV); Drug: Boceprevir (BOC)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Tobacco Cessation; HIV; AIDS
Interventions: Behavioral: Treatment as usual; Behavioral: AIR (Aspirations, Inspiration, Respiration)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Gay Men’s Health Crisis; The City College of New York; AIDS Center of Queens County; Bronx AIDS Services; Bronx Community Pride Center; Brooklyn AIDS Task Force; Fortune Society; Harlem United Community AIDS Center; Iris House; North Jersey Community Research Initiative
Recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C); Biological: rAd5 env A; Biological: rAd5 env B; Biological: rAd5 env C; Biological: rAd5 gag-pol; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: HIV; PCP; Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily; Drug: Atovaquone 1500 mg twice daily
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified October 2011 - Conditions: Substance Abuse; HIV
Interventions: Behavioral: Computer-facilitated HIV intervention; Behavioral: Attention Control
Sponsors: Treatment Research Institute; Treatment Research Institute; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified November 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir; Drug: ritonavir; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Cervical Cancer
Interventions: Drug: Nelfinavir; Drug: Cisplatin; Radiation: Pelvic External Beam Radiation Therapy; Radiation: Brachytherapy; Procedure: Pharmacokinetic Sampling; Procedure: Cervical Biopsy; Procedure: Pelvic Examination; Procedure: Pap Smear; Procedure: Audiogram; Procedure: Proctoscopy; Procedure: Cytoscopy; Procedure: Renal Ultrasound; Procedure: CT Scan; Procedure: Whole Body PET/CT Scan
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting - verified December 2011 - Condition: HIV Infection
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Tobira Therapeutics, Inc.
Recruiting - verified January 2012 - Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium; Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug: Pravastatin sodium
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: HIV Infection
Interventions: Dietary Supplement: Probiotics; Dietary Supplement: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Not yet recruiting - verified November 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Ribavirin; Biological: peginterferon alfa-2a
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Conditions: Adult Liposarcoma; Adult Synovial Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: recombinant interferon gamma; Biological: aldesleukin; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Biological: NY-ESO-1-specific T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Biological: Quadrivalent HPV Vaccine; Biological: Placebo Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Atripla (EFV/TDF/FTC); boosted darunavir & tenofovir/FTC; boosted atazanavir & tenofovir/FTC; raltegravir & tenofovir/FTC
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Human Immunodeficiency Virus
Intervention: Procedure: Genital and rectal swabbing
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: HIV
Intervention: Behavioral: Peer Navigator Intervention
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Not yet recruiting - verified October 2011 - Condition: Healthy
Intervention: Drug: dolutegravir
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; GlaxoSmithKline
Recruiting - verified December 2011 - Condition: HIV Infection
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified November 2011 - Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD; Drug: darunavir 800mg OAD; Drug: ritonavir 100mg OAD
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: HIV; AIDS
Intervention: Behavioral: Video or In-Person Presentation
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified August 2011 - Condition: HIV-1 Infection
Intervention: Drug: Rifaximin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Women's Health; HIV Infection; Genital Diseases, Female
Intervention:
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified October 2011 - Condition: Amphetamine-Related Disorders
Interventions: Drug: extended-release naltrexone; Drug: Placebo
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA); Alkermes
Not yet recruiting - verified October 2011 - Conditions: Hepatitis; HIV/AIDS
Interventions: Drug: Boceprevir; Drug: Peg-Interferon-alfa 2B; Drug: Ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Bacterial Vaginosis
Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol); Dietary Supplement: Placebo
Sponsors: Ohio State University; Ohio State University
Recruiting - verified October 2011 - Conditions: HIV Infections; Central Nervous System Neoplasms; Neurofibromatosis 1
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: HIV Infection; Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2011 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Conditions: Human Immunodeficiency Virus Infection; Hepatitis C
Intervention:
Sponsors: G & W Laboratories Inc.; G & W Laboratories Inc.; Alquest; SMART Biotech Ltd
Recruiting - verified October 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: Cobicistat; Drug: Darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified October 2011 - Conditions: Malignant Glioma; Glioblastoma; Brain Cancer
Interventions: Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: H5N1 Influenza
Interventions: Biological: Ad4-H5-VTN vaccination-tonsillar route; Biological: Ad4-H5-vaccination-oral route
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: HIV Infections
Interventions: Biological: VSV-Indiana HIV gag vaccine; Biological: Placebo injection (normal saline)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Gonorrhea; Chlamydia; Trichomoniasis; Syphilis; HIV Infections
Intervention: Behavioral: Intervention
Sponsors: University of Kentucky; University of Kentucky; National Institute of Mental Health (NIMH)
Not yet recruiting - verified September 2011 - Conditions: Castleman Disease; Castleman's Disease; Giant Lymph Node Hyperplasia
Interventions: Drug: Zidovudine; Drug: Tocilizumab; Drug: Valganciclovir
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
Sponsors: University of California, San Diego; University of California, San Diego; National Institutes of Health (NIH)
Recruiting - verified September 2011 - Condition: HIV-infection/Aids
Interventions: Dietary Supplement: Vitamin D3; Dietary Supplement: Placebo
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; National Institutes of Health (NIH); National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified November 2011 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: ribavirin
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Herpes Simplex Type II
Interventions: Drug: Tenofovir; Drug: placebo gel; Drug: tenofovir disoproxil fumarate (TDF); Drug: placebo tablets
Sponsors: University of Washington; University of Washington; CONRAD; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV Infection
Intervention: Drug: Polyphenon E
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified September 2011 - Condition: Opiate Dependence
Interventions: Other: Patient-Centered Methadone Treatment; Other: Methadone Treatment as usual
Sponsors: Friends Research Institute, Inc.; Friends Research Institute, Inc.
Recruiting - verified September 2011 - Condition: HIV Infections
Interventions: Biological: HIVAX; Biological: saline solution; Biological: HIVAX; Biological: Saline solution
Sponsors: GeneCure Biotechnologies; GeneCure Biotechnologies
Recruiting - verified September 2011 - Conditions: HIV; Risk Reduction Behavior
Intervention: Behavioral: MILE intervention
Sponsors: University of Southern California; University of Southern California; Charles Drew University of Medicine and Science; Centers for Disease Control and Prevention
Recruiting - verified August 2011 - Condition: HIV
Interventions: Drug: Twice-daily Darunavir/ritonavir; Drug: Once-daily Darunavir/ritonavir
Sponsors: Ruth M. Rothstein CORE Center; Ruth M. Rothstein CORE Center; Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Not yet recruiting - verified January 2012 - Conditions: Hepatitis C; HIV
Intervention: Drug: boceprevir; etravirine
Sponsors: University of Colorado, Denver; University of Colorado, Denver
Recruiting - verified August 2011 - Condition: Pulmonary Arterial Hypertension
Intervention: Device: Ventripoint Medical System
Sponsors: VentriPoint Diagnostics Ltd.; VentriPoint Diagnostics Ltd.
Recruiting - verified April 2012 - Conditions: HIV Infection; Hepatitis C
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Conditions: Contraceptive Usage; Opioid Dependence
Interventions: Behavioral: Contraceptive management program; Other: Usual care
Sponsors: University of Vermont; University of Vermont
Recruiting - verified December 2011 - Condition: HIV Prevention
Interventions: Behavioral: Integrated treatment program; Behavioral: Treatment as Usual
Sponsors: Rhode Island Hospital; Rhode Island Hospital; National Institute of Mental Health (NIMH)
Recruiting - verified August 2011 - Conditions: KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir; Drug: Rituximab/Liposoma Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: HIV; AIDS; Peripheral Neuropathy; Pain; Sleep
Interventions: Device: Splinting application to the lower extremities; Device: Splint liner application
Sponsors: Texas Woman's University; Texas Woman's University; Harris County Hospital District; DJO Incorporated
Recruiting - verified March 2012 - Conditions: HIV; Drug Use Disorders
Interventions: Behavioral: HEART to HAART; Behavioral: adherence counseling with the addition of smartphone control
Sponsors: University of Maryland; University of Maryland; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified August 2011 - Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Atazanavir
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Not yet recruiting - verified August 2011 - Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel; Drug: Depo-medroxyprogesterone acetate (DMPA); Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
Sponsors: CONRAD; CONRAD
Recruiting - verified May 2012 - Condition: Vitamin D Deficiency
Intervention:
Sponsors: University Hospitals of Cleveland; University Hospitals of Cleveland; Emory-Children's Center
Recruiting - verified February 2012 - Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012 - Condition: Opiate Dependence
Intervention: Behavioral: employment based reinforcement
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2010 - Conditions: Liver Diseases, Alcoholic; Alcoholism; HIV; Hepatitis C
Interventions: Other: Integrated Stepped Care (ISC); Other: Treatment as Usual
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Department of Veterans Affairs
Not yet recruiting - verified August 2011 - Condition: The Focus of the Study is the Treatment and Retention in Treatment for HIV+ ex Inmates.
Intervention: Behavioral: Peer Navigator
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Not yet recruiting - verified July 2011 - Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Eplerenone and lifestyle; Other: placebo and lifestyle
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Conditions: Tuberculosis; HIV Infections
Interventions: Drug: Rifapentine (RPT); Drug: Isoniazid (INH); Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012 - Condition: Myeloma
Interventions: Drug: G-CSF; Drug: Plerixafor; Procedure: Apheresis; Drug: Melphalan; Procedure: Stem cell re-infusion; Drug: Basiliximab; Device: CliniMACS CD25 microbeads and cell sorter
Sponsors: University of Chicago; University of Chicago
Recruiting - verified January 2012 - Condition: HIV-1 Infection
Interventions: Drug: Atripla; Drug: Calcium Carbonate; Drug: Vitamin D3; Drug: Placebo for calcium carbonate; Drug: Placebo for vitamin D3
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV/AIDS
Intervention: Behavioral: cognitive-behavioral therapy
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Yale University; Harbor Medical Inc.
Not yet recruiting - verified July 2011 - Condition: HIV-1 Infection
Interventions: Drug: Darunavir; Drug: Ritonavir; Drug: Tenofovir disoproxil fumarate; Drug: Emtricitabine; Drug: Placebo for Tenofovir disoproxil fumarate; Drug: Placebo for Maraviroc
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified September 2011 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Acquired Immunodeficiency Syndrome
Intervention:
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011 - Condition: Melanoma
Interventions: Drug: Ipilimumab; Drug: Temozolomide; Drug: Cisplatin; Drug: Interferon Alfa-2b; Drug: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: etoposide; Procedure: leukapheresis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: HIV; Sexually Transmitted Infections
Interventions: Behavioral: Connect 'n Unite; Behavioral: Wellness Promotion
Sponsors: Columbia University; Columbia University; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified January 2012 - Condition: HIV Infected
Intervention: Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: Correct and Consistent Condom Use.
Intervention: Behavioral: Homework Intervention Strategy
Sponsors: Indiana University; Indiana University
Recruiting - verified February 2012 - Conditions: Nicotine Dependence; Symptoms of Anxiety; HIV
Intervention: Behavioral: Integrated cognitive-behavioral therapy for smoking cessation and anxiety
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Southern Methodist University; University of Houston
Recruiting - verified July 2011 - Conditions: Sexual Risk Behavior; Childhood Sexual Abuse; Stress Disorders, Post-Traumatic
Interventions: Behavioral: Cognitive Processing Therapy for Sexual Risk; Behavioral: Supportive Psychotherapy; Behavioral: Sexual Risk Reduction Intervention
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Fenway Community Health; University of Miami
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: GLA-AF; Drug: GLA-SE; Other: Squalene
Sponsors: Rockefeller University; Rockefeller University; IDRI Corporation; Immune Design
Recruiting - verified February 2012 - Conditions: Drug Use; HIV; Hepatitis C
Intervention: Behavioral: Brief motivational intervention
Sponsors: Rhode Island Hospital; Rhode Island Hospital; National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011 - Conditions: HIV Negative; Adaptive Immunity; Innate Immunity
Interventions: Biological: VRC-HIVDNA016-00-VP; Biological: VRC-HIVADV014-00-VP
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011 - Condition: Vaginosis, Bacterial
Intervention: Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Sponsors: Eastern Virginia Medical School; Eastern Virginia Medical School; Merck
Recruiting - verified April 2012 - Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid; Biological: Aldesleukin
Sponsors: University of Alabama at Birmingham; Joseph Pressey, MD
Recruiting - verified December 2011 - Condition: HIV
Interventions: Behavioral: Standard Referral; Behavioral: Project Bridge
Sponsors: RTI International; RTI International; National Institute of Mental Health (NIMH)
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus-1
Interventions: Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: BMS-663068; Drug: Raltegravir; Drug: Raltegravir; Drug: Tenofovir; Drug: Tenofovir; Drug: Ritonavir; Drug: Atazanavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Leukemia; Chronic Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Procedure: NK cell infusion:; Drug: Interleukin-2; Drug: Anti-Thymocyte Globulin; Procedure: Allogeneic related Stem Cell Transplant; Drug: Tacrolimus; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Sexual Risk; Substance Use
Intervention: Other: Behavioral: HIV prevention intervention
Sponsors: Hunter College; Hunter College
Not yet recruiting - verified June 2011 - Condition: Influenza, Human
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome; Opiate Addiction; Drug Dependence
Intervention: Drug: Buprenorphine/naloxone
Sponsors: Yale University; Yale University; George Mason University; Howard University
Recruiting - verified April 2012 - Condition: HIV
Interventions: Behavioral: Monetary Incentive; Behavioral: Questionnaire Timing; Behavioral: HIV Test Offering
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified February 2012 - Conditions: Tuberculosis, Pulmonary; Mycobacterium Tuberculous; Antitubercular Agents; Tuberculosis, Mulutidrug-Resistant; Extensively Drug-Resistant; Extensibely Drug-Resistant Tuberculosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Substance Abuse; HIV Risk; Criminogenic Thinking; Shame; Guilt; Empathy
Interventions: Behavioral: MI plus IOC group intervention; Behavioral: Motivational Interview only
Sponsors: George Mason University; George Mason University; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Conditions: Impulsive Behavior; Substance Abuse; HIV Risk Behavior; Anxiety; Depression; Criminogenic Thinking
Interventions: Behavioral: REVAMP; Behavioral: TAU
Sponsors: George Mason University; George Mason University
Recruiting - verified June 2011 - Conditions: Substance Abuse; HIV Risk; Shame; Guilt; Empathy; Criminogenic Thinking
Interventions: Behavioral: Impact of Crime Modules; Behavioral: TAU
Sponsors: George Mason University; George Mason University; National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified June 2011 - Conditions: HIV; Opiate Dependence
Interventions: Behavioral: Abstinence-reinforcing contingency management intervention; Behavioral: Performance Feedback intervention
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University; National Institute on Drug Abuse (NIDA); The City University of New York
Not yet recruiting - verified June 2011 - Conditions: Bone Mineral Density; Bone; Osteoporosis
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified January 2012 - Conditions: Unsafe Sex; Risk Reduction
Interventions: Behavioral: PROJECT POWER; Behavioral: Power Health
Sponsors: Nova Southeastern University; Nova Southeastern University; John H. Stroger Hospital
Recruiting - verified November 2011 - Condition: HIV
Interventions: Drug: Vitamin D3; Drug: Placebo
Sponsors: Columbia University; Columbia University; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected WomenConditions: Human Immunodeficiency Virus (HIV); Self-efficacy; Self-esteem
Intervention: Behavioral: Ipod video
Sponsors: Duke University; Duke University; National Institute of Nursing Research (NINR)
Not yet recruiting - verified July 2011 - Conditions: Depression; HIV
Intervention: Other: Measurement-Based Care collaborative depression management
Sponsors: Duke University; Duke University; National Institute of Mental Health (NIMH); University of North Carolina, Chapel Hill; University of Alabama at Birmingham
Recruiting - verified June 2011 - Conditions: Cardiovascular Diseases; Hyperlipidemia; Obesity
Interventions: Behavioral: Physical Activity Group; Other: Standard Care Group
Sponsors: University of South Carolina; University of South Carolina; National Institute of Nursing Research (NINR)
Recruiting - verified February 2012 - Condition: HIV Prevention
Intervention: Drug: Tenofovir 1% vaginal gel
Sponsors: CONRAD; CONRAD
Recruiting - verified March 2012 - Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Aprepitant and Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011 - Condition: HIV
Intervention: Behavioral: Project Bridge
Sponsors: Friends Research Institute, Inc.; Friends Research Institute, Inc.; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2011 - Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors: Duke University; Duke University; Celgene Corporation; Genzyme
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Ring; Drug: Maraviroc Vaginal Ring; Other: Placebo Vaginal Ring; Drug: Dapivirine-Maraviroc Vaginal Ring
Sponsors: International Partnership for Microbicides, Inc.; International Partnership for Microbicides, Inc.
Recruiting - verified November 2011 - Conditions: HIV Infection; Substance Abuse
Interventions: Behavioral: Trans-theoretical Process of Change Model-self; Behavioral: Trans-theoretical Process of Change Model - interviewer
Sponsors: Nova Southeastern University; Nova Southeastern University; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Aldesleukin; Biological: Tumor Infiltrating Lymphocytes
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Alcohol Abuse
Interventions: Behavioral: CBI; Behavioral: TBI
Sponsors: University of Michigan; University of Michigan; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Condition: Hepatitis B
Interventions: Drug: Tenofovir; Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Pittsburgh
Not yet recruiting - verified February 2012 - Conditions: Methamphetamine Dependence; Substance Abuse; Methamphetamine Abuse
Interventions: Drug: Varenicline; Drug: Placebo
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified March 2012 - Condition: Human Immunodeficiency Virus (HIV) Infection
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Medication Adherence
Interventions: Behavioral: Adherence Counseling; Behavioral: General Health Counseling; Behavioral: Text Messages
Sponsors: University of Connecticut; University of Connecticut; National Institute of Nursing Research (NINR)
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Alcohol Consumption; Unsafe Sex
Interventions: Behavioral: Brief Motivational Intervention (BMI); Behavioral: Brief Advice
Sponsors: Brown University; Brown University; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Memorial Hospital of Rhode Island; Kent Hospital
Recruiting - verified November 2011 - Conditions: Hepatitis; HIV; Liver Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC); Washington DC Veterans Affairs Medical Center
Recruiting - verified February 2012 - Condition: HIV
Intervention: Behavioral: Treatment Advocacy
Sponsors: Children's Hospital Boston; Children's Hospital Boston; National Institute of Mental Health (NIMH)
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Diabetic Ulcer
Intervention: Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors: New York University School of Medicine; New York University School of Medicine; National Institutes of Health (NIH); Genzyme
Not yet recruiting - verified May 2011 - Condition: HIV Infection
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified November 2011 - Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg; Drug: Cenicriviroc 200 mg + Truvada; Drug: Sustiva + Truvada
Sponsors: Tobira Therapeutics, Inc.; Tobira Therapeutics, Inc.
Recruiting - verified October 2011 - Condition: HIV Disease
Interventions: Drug: HAART regimen; Drug: 3TC or FTC monotherapy
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: HIV
Interventions: Drug: Atazanavir Sulphate; Drug: Ritonavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: HIV; Hepatitis C; HIV and Hepatitis C Coinfection
Intervention:
Sponsors: University of Cincinnati; University of Cincinnati; Merck
Recruiting - verified January 2012 - Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Microbicide Delivery System Acceptability
Intervention:
Sponsors: The Miriam Hospital; The Miriam Hospital; ImQuest Pharmaceuticals, Inc.; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Behavioral: Positive STEPS
Sponsors: Fenway Community Health; Fenway Community Health; Children's Hospital Boston; Massachusetts General Hospital; Harvard University
Recruiting - verified April 2011 - Condition: HIV Lipodystrophy
Interventions: Drug: mecasermin; Drug: Placebo control
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: plerixafor; Drug: decitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Genzyme
Recruiting - verified June 2011 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Drug: cyclophosphamide; Biological: aldesleukin; Biological: autologous tumor cell vaccine; Other: laboratory biomarker analysis; Other: immunologic technique; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Biological: therapeutic autologous lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Non-Hodgkin's Lymphoma; Multiple Myeloma
Interventions: Drug: Plerixafor; Drug: Filgrastim
Sponsors: University of Florida; University of Florida
Recruiting - verified March 2012 - Conditions: Hazardous Drinking; HIV
Intervention: Behavioral: Brief alcohol intervention
Sponsors: Brown University; Brown University
Recruiting - verified October 2011 - Condition: HIV
Intervention: Drug: Raltegravir
Sponsors: University of Washington; University of Washington; Merck
Recruiting - verified October 2011 - Condition: HIV/AIDS
Interventions: Behavioral: Family-Based HIV prevention; Other: Adolescent Only Health Promotion
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified July 2011 - Condition: Tuberculosis
Interventions: Drug: TMC207; Drug: Rifampin; Drug: Rifabutin
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor; Drug: Plerixafor; Drug: Bevacizumab; Drug: Plerixafor; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Genzyme
Recruiting - verified February 2012 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Behavioral: Community Mobilization
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011 - Condition: Acquired Immunodeficiency Syndrome
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified October 2011 - Condition: Anal Cancer
Interventions: Drug: Tempol; Drug: 5-Fluorouracil; Drug: Mitomycin-C; Procedure: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ARTCondition: HIV-1 Infection
Intervention: Drug: Vorinostat
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Institutes of Health (NIH); Merck; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: HIV; Hepatitis C; Hepatitis B; Syphilis
Interventions: Device: Rapid tests for HIV, HCV, HBV, and syphilis; Device: HIV/HCV; Device: HIV/syphilis; Device: HIV only
Sponsors: California State University, Long Beach; California State University, Long Beach; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Behavioral Disorders Due to Psychoactive Substance Use
Interventions: Behavioral: HealthCall and Motivational Interviewing; Behavioral: Motivational Interviewing (MI); Behavioral: HIV/AIDS health education
Sponsors: Research Foundation for Mental Hygiene; Research Foundation for Mental Hygiene
Recruiting - verified March 2010 - Conditions: HIV; Depression; Drug Use
Interventions: Behavioral: Workshop; Behavioral: Workshop control
Sponsors: Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Conditions: Metastatic Melanoma; Skin Cancer
Interventions: Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Young Tumor Infiltrating Lymphocytes; Procedure: 1200 Gy Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Fanconi Anemia
Interventions: Biological: filgrastim; Drug: plerixafor; Procedure: leukapheresis; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: HIV Infection; Cardiovascular Disease; Inflammation
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; GlaxoSmithKline
Recruiting - verified November 2011 - Conditions: HIV; Medication Adherence; Substance Dependence
Intervention: Behavioral: Spiritual Self-Schema Therapy
Sponsors: Hunter College; Hunter College; Fordham University
Recruiting - verified February 2011 - Conditions: Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL
Intervention: Drug: Plerixafor Dose Escalation
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: GSK1349572 tablet formulation; Drug: GSK1349572 pediatric formulation
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV-1 Infection
Intervention: Drug: depo-medroxyprogesterone acetate
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: HIV Infection
Intervention: Drug: Interferon Alpha 2b
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: HIV-associated Co-morbidities
Interventions: Dietary Supplement: conventional vitamin D treatment versus a tiered/titrated dosing strategy; Drug: tiered/titrated vitamin D treatment
Sponsors: Mount Sinai School of Medicine; Andrea D. Branch; National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012 - Condition: HIV
Interventions: Drug: Raltegravir; Drug: Efavirenz
Sponsors: University of California, San Diego; University of California, San Diego; Merck
Recruiting - verified January 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Contraception
Intervention: Drug: one of 5 products
Sponsors: FHI 360; FHI 360; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: Healthy Volunteers
Intervention: Drug: Poly ICLC
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified January 2012 - Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012 - Condition: Transplantation Infection
Interventions: Drug: Cidofovir; Other: No Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: HIV Infection; Hepatitis C
Interventions: Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011 - Condition: AIDS
Interventions: Behavioral: FAmily CEntered (FACE) ACP; Behavioral: Healthy Living Control
Sponsors: Children's Research Institute; Children's Research Institute; St. Jude Children's Research Hospital; Johns Hopkins University; University of Miami
Recruiting - verified February 2012 - Conditions: HIV; Sexually Transmitted Diseases
Intervention: Behavioral: It's Your Game Tech
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; National Institute of Mental Health (NIMH)
Recruiting - verified March 2012 - Condition: Failure of Bone Marrow Graft
Intervention: Drug: Plerixafor
Sponsors: Duke University; Duke University; Genzyme
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine; Biological: IL-12; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: Healthy
Intervention: Drug: Non-medicated Intravaginal Ring
Sponsors: Population Council; Population Council; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Mental Health (NIMH); Microbicide Trials Network
Recruiting - verified May 2012 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: HIV Dementia
Intervention: Drug: Atorvastatin
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: HIV; HIV Lipodystrophy
Interventions: Drug: tesamorelin; Drug: placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine; Biological: MVA-CMDR Vaccine; Biological: Placebo PENNVAX-G Vaccine; Biological: Placebo MVA-CMDR Vaccine
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Alcohol Abuse; Alcohol Dependence
Interventions: Drug: ondansetron; Drug: placebo ondansetron; Drug: Ondansetron
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012 - Condition: Smoking
Interventions: Dietary Supplement: Broccoli sprout homogenate; Dietary Supplement: Alfalfa sprout homogenate
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Condition: HIV-1
Interventions: Drug: lersivirine; Drug: lersivirine; Drug: efavirenz; Drug: lersivirine; Drug: lersivirine; Drug: etravirine
Sponsors: Pfizer; Pfizer; ViiV Healthcare
Recruiting - verified May 2012 - Conditions: Crystal Methamphetamine Abuse; Crystal Methamphetamine Dependence
Interventions: Behavioral: Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR); Behavioral: Information, Motivation, Behavioral skills change approach to sexual risk reduction
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Fenway Community Health
Recruiting - verified May 2012 - Condition: HIV Infection
Interventions: Behavioral: Bruthas Project; Behavioral: Standard HIV Testing and Counseling
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Mental Health (NIMH)
Recruiting - verified January 2012 - Condition: Melanoma (Skin)
Interventions: Biological: aflibercept; Biological: aldesleukin
Sponsors: National Cancer Institute (NCI); Beckman Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Anal Cancer; Breast Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Lung Cancer; Nonneoplastic Condition; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: HIV; AIDS; Opioid Dependence; Drug Dependence
Intervention: Drug: Depot Naltrexone
Sponsors: Yale University; Yale University; Baystate Medical Center
Recruiting - verified August 2011 - Conditions: HIV; Alcoholism
Intervention: Drug: Naltrexone
Sponsors: University of Florida; University of Florida; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Interventions: Drug: atorvastatin; Drug: atorvastatin
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Pfizer
Recruiting - verified September 2011 - Condition: Laboratory Procedure Development and Validation
Intervention: Other: no intervention
Sponsors: University of Pittsburgh; Sharon Hillier; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: HIV; AIDS; Substance Use Disorders
Intervention: Behavioral: Resilient Affective Processing Therapy (RAPT)
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Condition: Human Immunodeficiency Virus
Intervention: Drug: emtricitabine/tenofovir disoproxil fumarate
Sponsors: Henry Ford Health System; Henry Ford Health System
Recruiting - verified June 2011 - Condition: ADHD
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012 - Conditions: HIV; Pregnancy
Intervention: Other: Vaginal lavage specimen
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified December 2011 - Conditions: Bacterial Vaginosis; Trichomoniasis; Candidiasis
Interventions: Drug: Placebo; Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Medication Adherence
Interventions: Device: Beeper; Device: ARemind
Sponsors: Dimagi Inc.; Dimagi Inc.; Massachusetts General Hospital; Boston University; Boston Medical Center; Harvard University; National Institute of Mental Health (NIMH)
Not yet recruiting - verified June 2011 - Conditions: HIV Infection; Bone Loss; Osteopenia; Osteoporosis
Intervention: Drug: Zoledronic acid
Sponsors: Emory University; Emory University
Recruiting - verified March 2012 - Condition: Reduction in Heavy Drinking in Patients With HIV
Interventions: Drug: Naltrexone; Other: Placebo + Medication Management/Medication Coaching
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2012 - Conditions: Fracture Fixation; Intra-Articular Fractures; Acetabulum
Intervention: Biological: Vitagel topical surgical hemostat
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified June 2011 - Conditions: HIV Infections; Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks; Drug: Placebo
Sponsors: University Hospitals of Cleveland; University Hospitals of Cleveland; National Institutes of Health (NIH); AstraZeneca
Recruiting - verified January 2012 - Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Merck; Gilead Sciences
Recruiting - verified February 2012 - Condition: HIV Positive Patient Receive Implant Supported Restoration
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Astra Tech AB
Recruiting - verified February 2012 - Conditions: HIV; Respiratory Infections; Fungal Pneumonia; Viral Pneumonia; Mycobacteria
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health Clinical Center (CC)
Recruiting - verified July 2011 - Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Metastatic Cancer; Metastatic Melanoma; Renal Cancer
Interventions: Genetic: Anti-VEGFR2 CAR CD8 plus PBL; Drug: Cyclophosphamide; Drug: Aldesleukin; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Pregnancy Outcome
Intervention:
Sponsors: Microbicide Trials Network; Microbicide Trials Network; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institutes of Health (NIH); Gilead Sciences; CONRAD
Recruiting - verified August 2011 - Conditions: LAD-1; DOCK8; MonoMAC
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: HIV; AIDS
Intervention:
Sponsors: George Washington University; George Washington University; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: Human Immunodeficiency Virus (HIV); Hepatitis C, Chronic
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified September 2010 - Conditions: HIV; Cancer
Intervention: Biological: Fluzone High Dose Vaccine Vs Fluzone
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012 - Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified January 2011 - Condition: HIV
Intervention: Procedure: Lymph node biopsy
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institutes of Health (NIH)
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Behavioral: Affect Management; Behavioral: General Health Promotion
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified July 2011 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Biological: rituximab; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Stage IIIc/IV Melanoma
Intervention: Biological: Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand
Sponsors: Baylor Research Institute; Baylor Research Institute; National Institutes of Health (NIH); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: HIV; Sexually Transmitted Diseases
Interventions: Behavioral: STYLEnS; Behavioral: Health Promotion
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Recruiting - verified March 2012 - Conditions: Hepatitis C; HIV
Intervention: Drug: Pegylated interferon with ribavirin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Fundacion de Investigacion de Diego
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV); Drug: tenofovir/emtricitabine (TDF/FTC); Drug: Atazanavir (ATV); Drug: Ritonavir; Procedure: Phlebotomy
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Society of Infectious Diseases Pharmacists; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Hepatitis B
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012 - Conditions: Substance Abuse; Contingency Management; Exercise
Intervention: Behavioral: Contingency Management
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011 - Condition: Healthy Adult Females
Intervention: Other: Pharmacokinetic Sampling
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Intervention: Biological: JS7 plasmid DNA and MVA62B vaccine
Sponsors: GeoVax, Inc.; GeoVax, Inc.; AIDS Research Consortium of Atlanta; University of Alabama at Birmingham; AIDS Research Alliance
Recruiting - verified December 2011 - Condition: HIV
Intervention: Drug: Lopinavir/ritonavir
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Risk Reduction Behavior; Health Behavior; Sexual Behavior; Adolescent Behavior; Cannabis
Interventions: Behavioral: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY); Behavioral: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH); Behavioral: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Sponsors: University of New Mexico; University of New Mexico; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011 - Conditions: Metastatic Colorectal Cancer; Metastatic Gastric Cancer; Metastatic Pancreatic Cancer; Metastatic Hepatocellular Carcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: CD8+ young TIL; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Anal Cancer; Neoplasm of Uncertain Malignant Potential; Nonneoplastic Condition; Precancerous Condition
Interventions: Other: clinical observation; Procedure: infrared photocoagulation therapy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: HIV Infection
Intervention: Drug: Raltegravir
Sponsors: Southern California Institute for Research and Education; Southern California Institute for Research and Education; Merck
Recruiting - verified May 2012 - Condition: Contraception
Interventions: Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2; Drug: levonorgestrel patch with BMI <32 kg/m2; Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2; Drug: levonorgestrel patch with BMI <32 kg/m2
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Health Decisions
Recruiting - verified February 2012 - Condition: HIV
Interventions: Behavioral: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test; Device: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Sponsors: University of Washington; University of Washington; Public Health - Seattle and King County; National Institute of Mental Health (NIMH)
Recruiting - verified February 2012 - Conditions: HIV; AIDS; Epidemiology; Prevention
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012 - Conditions: HIV+; Fatigue; Unmet Vocational Goals
Interventions: Behavioral: Behavioral Activation Therapy-; Behavioral: Supportive Counseling
Sponsors: Research Foundation for Mental Hygiene; Research Foundation for Mental Hygiene
Recruiting - verified November 2011 - Condition: HIV Infection
Interventions: Behavioral: Linkage-to-Care Component: Financial Incentive (FI); Behavioral: Linkage-to-Care Component: Standard of Care (SOC); Behavioral: Viral Suppression Component: FI; Behavioral: Viral Suppression Component: SOC; Behavioral: Prevention for Positives Component: Counseling and SOC; Behavioral: Prevention for Positives Component: SOC
Sponsors: HIV Prevention Trials Network; HIV Prevention Trials Network; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: HIV Positive
Intervention:
Sponsors: University of California, San Diego; Zuniga De Nuncio, Maria; National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: G-CSF (filgrastim) plus Plerixafor Injection; Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors: Genzyme; Genzyme
Recruiting - verified April 2012 - Condition: Acute Myelogenous Leukemia
Interventions: Drug: Plerixafor; Drug: Clofarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genzyme
Recruiting - verified April 2012 - Condition: Drug Usage
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma
Intervention: Drug: Sargramostim and plerixafor
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified November 2011 - Condition: Major Depression
Interventions: Behavioral: Interpersonal Psychotherapy; Behavioral: Problem-Solving Therapy; Behavioral: Brief Supportive Psychotherapy
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Recruiting - verified February 2012 - Conditions: HIV Infections; Menopause
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified January 2012 - Conditions: HIV Infections; Hepatitis; Sexually Transmitted Infections
Interventions: Behavioral: Traditional Prevention; Behavioral: Web-based Prevention
Sponsors: National Development and Research Institutes, Inc.; National Development and Research Institutes, Inc.; National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011 - Conditions: Lymphoma; HIV
Intervention: Procedure: Autologous transplant
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified January 2012 - Conditions: HIV; AIDS
Intervention: Behavioral: Skills Building - Motivational Interviewing
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified June 2011 - Conditions: Stimulant-Related Disorders; HIV; HIV Infections
Intervention: Drug: Truvada
Sponsors: Friends Research Institute, Inc.; Friends Research Institute, Inc.; University of California, Los Angeles
Recruiting - verified October 2011 - Conditions: HIV-1 Infection; Neuropathic Pain
Intervention: Drug: pregabalin (Lyrica)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel; Other: Placebo gel
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Drug Abuse; HIV Risk Behavior
Interventions: Behavioral: Computerized brief intervention; Behavioral: Counselor delivered brief intervention
Sponsors: Friends Research Institute, Inc.; Friends Research Institute, Inc.; National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011 - Conditions: Hazardous Alcohol Use; Binge Drinking; High Risk Sexual Behaviors; HIV Risk Reduction; HIV Infection
Interventions: Behavioral: Computerized brief alcohol intervention with IVR booster calls; Behavioral: Computer delivered brief alcohol intervention; Behavioral: Attention Control
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified June 2011 - Conditions: HIV Medication Adherence; Methamphetamine Use; Sexual Risk; Poly-substance Use; HIV Infections
Interventions: Behavioral: Motivational Interviewing + Cognitive Behavioral Skills Training; Behavioral: Education Attention Control
Sponsors: Hunter College; Hunter College
Recruiting - verified June 2011 - Conditions: Substance Abuse; HIV Infections
Intervention: Behavioral: Stonewall Project
Sponsors: University of California, San Francisco; University of California, San Francisco; California HIV/AIDS Research Program
Recruiting - verified March 2012 - Condition: Normal Volunteer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: Drug Abuse
Interventions: Behavioral: Computer-delivered Brief Intervention (CBI); Behavioral: Intervener-delivered Brief Intervention (IBI); Behavioral: Adapted Motivational Enhancement Therapy (AMET); Behavioral: Enhanced Usual Care (EUC)
Sponsors: University of Michigan; University of Michigan; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Nelfinavir
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012 - Conditions: Birth Defects; Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
Sponsors: ViiV Healthcare; ViiV Healthcare; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: HIV Infections
Intervention: Procedure: Blood collection
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: HIV; Cardiovascular Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Myeloma; Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Emory University; Emory University; Genzyme
Recruiting - verified March 2012 - Conditions: HIV; HIV Infections
Intervention:
Sponsors: George Washington University; George Washington University
Recruiting - verified September 2010 - Conditions: Alcohol Dependence; Problem Drinking; Hazardous Drinking; Human Immunodeficiency Virus; AIDS
Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation); Drug: Placebo
Sponsors: Yale University; Yale University; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011 - Condition: Lymphoma
Interventions: Drug: lenalidomide; Drug: temsirolimus; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified November 2010 - Conditions: Anaplastic Astrocytoma; Anaplastic Ependymoma; Anaplastic Meningioma; Anaplastic Oligodendroglioma; Brain Stem Glioma; Ependymoblastoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Grade III Meningioma; Meningeal Hemangiopericytoma; Mixed Glioma; Pineal Gland Astrocytoma; Brain Tumor
Interventions: Biological: therapeutic allogeneic lymphocytes; Biological: aldesleukin; Other: laboratory biomarker analysis; Procedure: positron emission tomography
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified November 2011 - Condition: HIV Infection
Interventions: Biological: AGS-004; Biological: Placebo
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified November 2011 - Conditions: Bone Marrow; Bone Marrow Stromal Cells; Mesenchymal Stem Cells; Blood Donors
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified November 2011 - Conditions: Carcinoma, Adenoid Cystic; Head and Neck Neoplasms
Intervention: Drug: Nelfinavir
Sponsors: University of Iowa; University of Iowa; Holden Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: plerixafor; Biological: filgrastim; Drug: cyclophosphamide; Procedure: autologous hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention:
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
Intervention: Drug: Plerixafor
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme
Recruiting - verified May 2012 - Conditions: HIV; HIV Infections
Intervention: Drug: Valacyclovir
Sponsors: University of Washington; University of Washington
Recruiting - verified November 2011 - Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Adenocarcinoma of the Pancreas; Pancreatic Cancer; Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Drug: nelfinavir mesylate; Radiation: stereotactic body radiation therapy; Radiation: hypofractionated radiation therapy; Procedure: therapeutic conventional surgery; Other: pharmacological study; Genetic: polymorphism analysis; Other: pharmacogenomic studies; Genetic: protein expression analysis
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: HIV Infection; HIV Infections
Intervention: Genetic: SB-728-T
Sponsors: Sangamo Biosciences; Sangamo Biosciences
Recruiting - verified December 2011 - Conditions: HIV Infection; HIV Infections
Intervention:
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Hepatitis C
Interventions: Other: Ribavrin; Drug: Abacavir plus Ribavirin
Sponsors: Johns Hopkins University; Johns Hopkins University; GlaxoSmithKline; University of Nebraska
Recruiting - verified January 2010 - Condition: Drug Abuse Among Patients Admitted to a Trauma Department.
Interventions: Behavioral: Brief advice; Behavioral: Brief Intervention plus Booster Session (BMI+B); Behavioral: Brief Intervention
Sponsors: University of Texas at Austin; University of Texas at Austin; National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2012 - Conditions: High Triglyceride Level; HIV Infection
Intervention: Drug: Lovaza
Sponsors: Tufts University; Todd Conley; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: HIV Infections
Interventions: Drug: Emtricitabine (FTC); Drug: Tenofovir disoproxil fumarate (TDF); Drug: Efavirenz (EFV)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Multiple Myeloma; Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor
Sponsors: Shi, Patricia, M.D.; Shi, Patricia, M.D.; Genzyme
Recruiting - verified September 2011 - Conditions: HIV Infections; Acquired Immunodeficiency Syndrome; Medication Adherence
Intervention: Behavioral: MedCHEC tablet computer and Adherence Care
Sponsors: Boston University; Boston University; National Institute of Mental Health (NIMH); Department of Veterans Affairs; VA Boston Healthcare System; VA Greater Los Angeles Healthcare System; San Diego State University; Tufts University
Recruiting - verified February 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Renal Cell Carcinoma
Intervention: Drug: Aldesleukin
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012 - Conditions: HIV Infection; Osteopenia; Osteoporosis
Intervention:
Sponsors: Emory University; Emory University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2012 - Conditions: HIV Infections; Hepatitis C Virus
Intervention:
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified February 2012 - Conditions: Melanoma; Carcinoma, Renal Cell
Intervention: Drug: Recombinant Human IL-15
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Sarcoma
Interventions: Drug: bortezomib; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Stem Cell Transplant Patients
Intervention: Drug: G-CSF +/- AMD3100
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Condition: HIV Infections
Interventions: Other: CARE+ Spanish computer counseling session; Other: CARE+ Spanish brief computer risk assessment session
Sponsors: New York University; New York University; St. Luke's-Roosevelt Hospital Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: ritonavir; Procedure: therapeutic conventional surgery
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota; Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012 - Condition: Substance Use Disorder
Interventions: Behavioral: Computerized brief intervention; Behavioral: Computerized health screening; Behavioral: Computerized assessment; Behavioral: Therapist-delivered motivational intervention
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Condition: Trichomonas Infections
Intervention:
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center; Mississippi State Department of Health
Recruiting - verified April 2012 - Condition: Influenza Virus
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Behavioral: Modified client adherence profiling and intervention tailoring (CAP-IT)
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV Infections
Interventions: Biological: WT-gag-TCR modified T cells; Biological: α/6-gag-TCR modified T cells; Other: STI or Drug Holiday
Sponsors: University of Pennsylvania; University of Pennsylvania; Adaptimmune Ltd.
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Behavioral: Enhanced nursing telephone support; Behavioral: Standard care
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: Opiate Dependence
Intervention: Behavioral: Linkage
Sponsors: Butler Hospital; Butler Hospital; Boston Medical Center
Recruiting - verified March 2012 - Condition: High Risk Non-Hodgkin's Lymphoma
Interventions: Biological: Rituximab; Biological: Interleukin-2
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012 - Condition: Hepatitis B
Interventions: Drug: Simvastatin; Drug: Tenofovir; Drug: Entecavir
Sponsors: Bader, Ted, M.D.; Bader, Ted, M.D.
Recruiting - verified June 2011 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012 - Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Hodgkin Lymphoma; Non Hodgkin Lymphoma; Kaposi's Sarcoma; Gastric Cancer; Nasopharyngeal Cancer
Interventions: Other: FIAU-PET-CT scans; Other: FIAU-PET-CT scan
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Raltegravir (RAL); Drug: Atazanavir (ATV); Drug: Ritonavir (RTV); Drug: Tenofovir (TDF); Drug: Etravirine (ETV); Drug: Darunavir (DRV); Drug: Maraviroc (MVC); Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Infertility; HIV Infections
Interventions: Other: Sperm washing and testing for HIV contamination; Procedure: Intrauterine Insemination
Sponsors: University of Missouri-Columbia; University of Missouri-Columbia
Available - verified September 2011 - Conditions: Malaria; Malaria Vaccines; Plasmodium Falciparum Malaria
Intervention: Biological: Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine
Sponsors: National Institutes of Health Clinical Center (CC); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified March 2011 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; HIV-associated Hodgkin Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Secondary Myelodysplastic Syndromes
Interventions: Procedure: leukapheresis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Other: DNA analysis; Other: RNA analysis; Other: flow cytometry; Other: reverse transcriptase-polymerase chain reaction; Other: nucleic acid sequencing; Other: protein expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Cardiovascular Disease; HIV; Atherosclerosis; Inflammation; Statins, HMG-CoA; HIV Infections
Interventions: Drug: atorvastatin; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012 - Conditions: WHIMS; Neutrophil Disorder; Myelokathexis; Hypogammaglobulinemia
Intervention: Drug: Mozobil (TM)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Etravirine (Intelence)
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Lymphoma; B-cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention: Drug: Highly active antiretroviral therapy (HAART)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA-016-00-VP; Biological: VRCHIVADV014-00-VP
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Cystitis; Bladder Diseases
Intervention: Drug: Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Gilead Sciences
Not yet recruiting - verified March 2012 - Conditions: Acute Myelogenous Leukemia; Leukemia
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Genzyme; Onyx Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Atripla
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Bristol-Myers Squibb; Gilead Sciences
Recruiting - verified December 2011 - Condition: HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin; Drug: Bevacizumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Oncology
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Alendronate; Drug: Alendronate placebo; Dietary Supplement: Calcium carbonate/vitamin D
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected PeopleCondition: HIV Infection
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: HIV Infections
Intervention: Biological: SAV001-H
Sponsors: Sumagen; Sumagen
Recruiting - verified March 2012 - Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Large Cell Lymphoma
Interventions: Genetic: Anti-CD19-CAR Transduced PBL; Drug: Aldesleukin; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Renal Cancer; Kidney Cancer
Interventions: Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn; Drug: Aldesleukin; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Opiate Addiction
Interventions: Other: Brief Intervention with Buprenorphine initiation; Behavioral: Brief Intervention
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100); Drug: bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Genzyme
Recruiting - verified May 2012 - Condition: Leukemia, Myeloid, Acute
Interventions: Drug: G-CSF; Drug: Plerixafor; Drug: Mitoxantrone; Drug: Etoposide; Drug: Cytarabine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Cryptococcal Meningitis; HIV Infections
Interventions: Drug: Fluconazole; Drug: Amphotericin B
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: Autoinflammatory Syndromes; Physical Urticaria
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Conditions: HIV Infections; Drug Abuse
Interventions: Drug: Disulfiram; Drug: Disulfiram + Efavirenz; Drug: Disulfiram + Atazanavir; Drug: Disulfiram + Ritonavir
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Condition: HIV Infections
Intervention: Behavioral: Entre Culturas: Navigating Culture, Identity, and HIV Risk
Sponsors: Nova Southeastern University; Nova Southeastern University
Recruiting - verified November 2011 - Conditions: HIV Infections; Hepatitis C
Interventions: Drug: Alcohol; Drug: Alcohol placebo
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine; Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine; Biological: DNA vaccine placebo; Biological: HIV-1 recombinant adenovirus vaccine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network
Recruiting - verified May 2012 - Conditions: Idiopathic CD4+ Lymphocytopenia; Cryptococcal Meningitis; Warts
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Drug: cyclophosphamide; Procedure: biopsy; Biological: aldesleukin; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Other: immunoenzyme technique; Biological: therapeutic allogeneic cytotoxic T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: HIV (Human Immunodeficiency Virus); Metabolic Syndrome; HIV Infections
Intervention: Behavioral: Dietary Intervention
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified June 2011 - Conditions: Acute HIV Infection; HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Janssen Pharmaceuticals
Recruiting - verified December 2011 - Conditions: HIV; HIV Infections; Pregnancy
Interventions: Drug: TMC114 (darunavir); Drug: ritonavir; Drug: TMC125 (etravirine); Drug: TMC278 (rilpivirine); Drug: TMC114 (darunavir)
Sponsors: Tibotec, Inc; Tibotec, Inc; Janssen Services, LLC
Recruiting - verified May 2012 - Conditions: HIV; HIV Infections
Intervention: Behavioral: Video
Sponsors: North Bronx Healthcare Network; North Bronx Healthcare Network; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: HIV Infections; Sexually Transmitted Infections
Interventions: Behavioral: Male Sexual Health Program; Behavioral: Focus on the Future Program
Sponsors: University of Kentucky; University of Kentucky; Louisiana State University Health Sciences Center in New Orleans; Carolinas Healthcare System
Recruiting - verified August 2011 - Conditions: HIV Infection; Cardiovascular Disease; Inflammation; HIV Infections
Interventions: Drug: Maraviroc; Drug: placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI); Pfizer
Recruiting - verified November 2011 - Conditions: HIV Infection; Inflammation; Cardiovascular Disease; HIV Infections
Interventions: Drug: raltegravir; Drug: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; National Heart, Lung, and Blood Institute (NHLBI); Merck
Recruiting - verified November 2011 - Conditions: HIV; Substance Abuse; HIV Infections
Interventions: Behavioral: Intensive Case Management; Drug: Buprenorphine; Behavioral: Money Management
Sponsors: Yale University; Yale University
Recruiting - verified June 2011 - Condition: Idiopathic CD4+ T-Lymphocytopenia
Intervention: Drug: CYT107
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011 - Condition: Substance Abuse
Intervention: Behavioral: contingency management
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011 - Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Cancer; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Interventions: Drug: Chloroquine; Drug: Placebo
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
Interventions: Drug: Raltegravir; Drug: Atazanavir; Other: Standard treatment regimen
Sponsors: Yale University; Yale University; Bristol-Myers Squibb; Merck
Recruiting - verified February 2012 - Conditions: HSV-2; HIV; HIV Infections
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; GlaxoSmithKline
Recruiting - verified August 2011 - Conditions: HIV Infections; HIV-1
Intervention: Drug: TMC278
Sponsors: Tibotec Pharmaceuticals, Ireland; Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2012 - Condition: HIV Lipodystrophy
Interventions: Drug: Growth hormone; Drug: Growth Hormone Releasing Hormone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus (HIV)
Intervention: Drug: Maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: HIV Infections; AIDS; Opportunistic Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Cocaine Dependence; Cocaine-Related Disorders; Opioid-Related Disorders
Interventions: Drug: Airipiprazole; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011 - Conditions: Cardiovascular Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Biological: allogeneic large multivalent immunogen breast cancer vaccine; Biological: aldesleukin
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011 - Condition: Human Immunodeficiency Virus Infections
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Other: educational intervention
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: HIV
Intervention: Behavioral: Online social networking HIV prevention
Sponsors: Colorado School of Public Health; Colorado School of Public Health; National Institute of Nursing Research (NINR); Internet Sexuality Information Services (ISIS); Columbia University; Rutgers University
Recruiting - verified July 2009 - Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease
Interventions: Drug: AMD3100; Drug: G-CSF; Procedure: Apheresis
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Substance Abuse; HIV Infections
Interventions: Behavioral: contingency management; Behavioral: contingency management
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011 - Conditions: Smoking; HIV Infections
Interventions: Drug: Varenicline tartrate; Drug: Nicotine Replacement Therapy; Other: Biological Control; Behavioral: Motivational Interview
Sponsors: Ohio State University; Ohio State University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Pulmonary Tuberculosis
Interventions: Drug: rifampin; Drug: rifapentine; Drug: rifapentine; Drug: rifapentine
Sponsors: Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: ARV regimen chosen by treating physician
Sponsors: University of North Carolina, Chapel Hill; Kristine Patterson, MD; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: HIV Infections; Hyperlipidemia
Intervention: Drug: Atorvastatin
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Conditions: Metastatic Melanoma; Metastatic Renal Cell Cancer; Metastatic Cancer
Interventions: Biological: therapeutic autologous lymphocytes; Biological: aldesleukin; Drug: cyclophosphaide; Drug: fludarabine phosphate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Cocaine Addiction
Interventions: Behavioral: I/GDC + VR/CER; Behavioral: I/GDC
Sponsors: Duke University; Duke University; National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011 - Condition: Lung Cancer
Interventions: Biological: EGFRBi-armed autologous activated T cells; Biological: aldesleukin; Biological: sargramostim
Sponsors: Roger Williams Medical Center; Roger Williams Medical Center
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention: Drug: Cell Transfer
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012 - Condition: Opiate Dependence
Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011 - Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
Sponsors: James Graham Brown Cancer Center; James Graham Brown Cancer Center
Recruiting - verified September 2011 - Conditions: Chronic Hepatitis B e Antigen Positive; Chronic Hepatitis B e Antigen Negative
Intervention: Drug: Tenofovir/ & Emtricitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011 - Condition: HIV Infections
Interventions: Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518); Drug: Raltegravir (MK-0518)
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Conditions: HIV Infections; Lipodystrophy
Intervention: Drug: Metreleptin (Leptin)
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011 - Conditions: HIV-Dementia; HIV-Associated Cognitive Motor Complex; AIDS Encephalopathy; AIDS Dementia Complex; AIDS-Related Dementia Complex; HIV Infections; Healthy
Intervention: Drug: [11C]PBR28
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified August 2011 - Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
Recruiting - verified May 2012 - Conditions: HIV Infections; Coronary Atherosclerosis
Intervention:
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Vaccine
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Oral Hygiene; HIV Infections; Mouth Diseases
Intervention: Behavioral: Case-management linkage intervention
Sponsors: University of Miami; University of Miami; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified January 2012 - Condition: Cocaine Dependence
Interventions: Drug: Modafinil; Drug: placebo; Behavioral: Cognitive Behavioral Therapy (CBT)
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified November 2011 - Condition: Lymphoma
Interventions: Drug: carmustine; Drug: cyclophosphamide; Drug: etoposide; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy; Biological: G-CSF
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012 - Condition: Pneumocystis Pneumonia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: CMV Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Samples
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Liver Fibrosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified March 2012 - Condition: Stem Cell Mobilization
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012 - Conditions: Metastatic Melanoma; Renal Cell Cancer
Intervention: Biological: aldesleukin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Opioid-Related Disorders
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Condition: HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified March 2012 - Conditions: AIDS-Related Primary Central Nervous System Lymphoma; HIV
Interventions: Drug: Methotrexate; Biological: rituximab; Procedure: antiviral therapy; Drug: leucovorin calcium
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention: Procedure: blood draw
Sponsors: Rockefeller University; Rockefeller University
Recruiting - verified January 2012 - Conditions: Drug Abuse; HIV Infections
Intervention:
Sponsors: University of Florida; University of Florida; National Institute on Drug Abuse (NIDA); Johns Hopkins University
Recruiting - verified March 2012 - Condition: HIV Infections
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Condition: HIV Infection
Intervention: Drug: Efavirenz
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Available - verified January 2012 - Condition: Blood Component Removal
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; HIV Infection; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Hemoglobinopathies; Hemolysis; Iron Deficiency and Overload; Anemias
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011 - Condition: Giant Lymph Node Hyperplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Healthy
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Conditions: Hepatitis C; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012 - Conditions: Healthy; Blood Component Removal
Intervention: Drug: AMD3100
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011 - Condition: Blood Component Removal
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012 - Conditions: Urticaria; Arthropathy; Lymphadenopathy; Nervous System Anomalies
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Condition: HIV Infections
Intervention: Drug: Current ARV medications
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Conditions: HIV Seronegativity; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Conditions: Rheumatic Diseases; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012 - Condition: HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Conditions: HIV Infections; Pregnancy Complications, Infectious
Intervention: Behavioral: Adherence assessment
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012 - Conditions: Cancer; HIV Infection; Skin Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Virus Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified May 2012 - Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Drug: CD34+ cells transduced with ADA retrovir
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012 - Condition: Common Variable Immunodeficiency
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Head and Neck Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified July 2011 - Condition: Hemochromatosis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institutes of Health Clinical Center (CC)
Recruiting - verified August 2011 - Conditions: HIV Infection; Kaposi's Sarcoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011 - Conditions: AIDS Related Lymphoma; HIV Infection
Interventions: Biological: Rituximab; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Immunologic Deficiency Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2011 - Condition: HIV Infections
Intervention:
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012 - Condition: HIV Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID); Washington Hospital Center
Recruiting - verified January 2012 - Conditions: HIV Infection; Viremia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011 - Conditions: HIV Infection; Immunologic Deficiency Syndrome
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012 - Conditions: AIDS Associated Nephropathy; Focal Glomerulosclerosis; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011 - Condition: HIV Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011 - Condition: HIV Infection
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012 - Conditions: AIDS Associated Nephropathy; Focal Glomerulosclerosis; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011 - Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Acquired Immunodeficiency Syndrome; Neoplasm; Skin Disease; HIV Infections
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: HIV Infection; Neoplasm
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cryptococcosis; Lymphopenia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Conditions: Alcoholic Intoxication; Alcoholism; Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified June 2011


